Abstract
Congenital disorders of glycosylation (CDG) are clinically and biochemically versatile disorders affecting the N- or O-glycosylation of proteins or lipids. The rapidly growing number of distinct CDG increasingly makes clear that a comprehensive screening for the vast majority of CDG is not possible on a simple basis. The prevailing methods for the screening and the diagnosis of CDG are presented, showing the potential and the limits of the diagnostic and screening tools used, orientated at suitability for daily use. Although valid and comprehensive diagnostic tests for CDG type I exist, there are limitations in the diagnosis of CDG type II, and many undiagnosed CDG type IIs must be expected. The apparent limitations of the methods used at present imply a necessity for new and broad diagnostic tools that comprise modern methodology to meet the requirements for screening tools.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
